C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden
- 16 December 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 26 (1), 37-42
- https://doi.org/10.1007/s10096-006-0239-3
Abstract
The aim of this study was to evaluate the synthetic C6 peptide test as a first-line test in a two-tiered scheme for Borrelia serology in a clinically well-characterized population of patients with Lyme borreliosis in Kalmar County, Sweden. The study population consisted of a prospective group (n = 200), a control group (n = 255), and a retrospective group (n = 29). The test panel consisted of the Immunetics Quick ELISA C6 Borrelia assay kit (Immunetics, Cambridge, MA, USA), the Virotech Borrelia burgdorferi ELISA (Genzyme Virotech, Rüsselsheim, Germany), and the Liaison Borrelia CLIA (DiaSorin, Saluggia, Vercelli, Italy). Seroprevalence among 200 healthy blood donors was significantly lower in the C6 test (8%) compared to the Virotech ELISA (14%) and the Liaison CLIA (12%). In convalescent sera (2–3 months and 6 months post infection) from 158 patients with erythema migrans, the seropositivity in the C6 test was also significantly lower compared to both the Virotech ELISA and the Liaison CLIA. Serosensitivity in the acute phase of erythema migrans and other clinical manifestations of borreliosis did not differ significantly between the C6 test and the Virotech ELISA or the Liaison CLIA. Overall, a positive C6 test seems to correlate well with acute borreliosis. Cross-reactivity was lower in the C6 test in sera positive for Epstein-Barr virus infection as compared to the Virotech ELISA. This study supports the use of the C6 test as a screening test for borreliosis, in endemic areas.Keywords
This publication has 13 references indexed in Scilit:
- Analysis of Borrelia burgdorferi IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISAClinical Microbiology & Infection, 2005
- Guidelines for the diagnosis of tick-borne bacterial diseases in EuropeClinical Microbiology & Infection, 2004
- Lyme borreliosis in Sweden - diagnostic performance of five commercial Borrelia serology kits using sera from well-defined patient groups. Brief reportAPMIS, 2004
- Antibody Response to IR6, a Conserved Immunodominant Region of the VlsE Lipoprotein, Wanes Rapidly after Antibiotic Treatment ofBorrelia burgdorferiInfection in Experimental Animals and in HumansThe Journal of Infectious Diseases, 2001
- Antigenic Conservation of an Immunodominant Invariable Region of the VlsE Lipoprotein among European Pathogenic Genospecies ofBorrelia burgdorferiSLThe Journal of Infectious Diseases, 2000
- Overdiagnosis and overtreatment of Lyme neuroborreliosis are preventablePublished by Oxford University Press (OUP) ,1999
- Evaluation of fifteen commercially available serological tests for diagnosis of Lyme borreliosis.European Journal of Clinical Microbiology & Infectious Diseases, 1999
- An Epidemiologic Study of Lyme Disease in Southern SwedenNew England Journal of Medicine, 1995
- Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.1995
- Tick-borne Borreliosis in the Archipelage of Southern SwedenScandinavian Journal of Infectious Diseases, 1993